74
Participants
Start Date
August 25, 2021
Primary Completion Date
June 30, 2026
Study Completion Date
June 30, 2026
Cisplatin
Given IV
Elimusertib
Given PO
Gemcitabine Hydrochloride
Given IV
NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
University of Pittsburgh Cancer Institute (UPCI), Pittsburgh
National Cancer Institute Developmental Therapeutics Clinic, Bethesda
National Institutes of Health Clinical Center, Bethesda
Ohio State University Comprehensive Cancer Center, Columbus
University of Wisconsin Carbone Cancer Center - University Hospital, Madison
University of California Davis Comprehensive Cancer Center, Sacramento
University Health Network-Princess Margaret Hospital, Toronto
National Cancer Institute (NCI)
NIH